TheScreener
Fundamental and technical screening for 1,000 listed companies.
Use ⌘K to search stocks, screens, and features instantly.
Morepen Laboratories Ltd
MOREPENLABSmall CapNSEBSE
Healthcare · Diagnostic Devices & APIs
₹104.11up 7.41up 7.66 percentas of 28 Aug 2026
Book value ₹24.50Div yield 0.19%
Key metrics
- Market Cap
- 5,819.82 ₹ cr
- P/E
- 55.90 x
- P/B
- 4.25 x
- ROE
- 9.42%
- ROCE
- 10.72%
- Debt to Equity
- 0.36 x
- Net Margin
- 12.06%
- Dividend Yield
- 0.19%
- Revenue Growth (YoY)
- 34.07%
Observations
Mechanical observations generated from stored data, not analysis or opinion. Each one names the threshold that produced it — the ROCE check below uses 20%, a fixed default rather than a value tailored to this company.
- ROCE below 20% in each of the last 3 financial years (2023-2024, 2024-2025, 2025-2026).
- Revenue declined year-on-year in 1 of the last 3 years.
- Net margin declined year-on-year in 1 of the last 3 years.
- Promoter holding 35.6% (pledge data not available).
MOREPENLAB
₹104.11up 7.66 percent
EOD Synced: 28 Aug 2026 18:30 ISTOverview & Live Price Chart
Executive Investment Verdict & Quality Synthesis
Autonomous V2Multi-dimensional quantitative synthesis across capital efficiency, forensic accounting, intrinsic valuation, and ownership governance.
Factual Quantitative Consensus
1. Capital Efficiency & MoatCapital Intensive
7.96%ROCE
ROE: 7.61%·P/B: 4.25x
2. Forensic Health & SolvencyPiotroski 4/9 · Adequate Health
4/9Piotroski Score
Altman: 6.5 (Safe Zone)
3. Valuation & DCF Spread-51.3% Valuation Premium
₹51DCF Fair Value
CMP: ₹104.1
4. Ownership & GovernanceClean Promoter Holding
35.65%Promoter Stake
Pledged: 0.0%·Inst: —
Institutional Factor Scores
QVGM Factor Grade Matrix
Institutional Multi-Factor Profile (QVGM)
Composite 0–100 percentile ranks normalized across all 500 universe constituents
Rank #30 of 46 in HealthcareQVGM 56/100
Quality (Q)45
ROE, ROCE, Margins & Cash Conversion
Value (V)32
P/E, P/B, EV/EBITDA vs Sector Benchmarks
Growth (G)58
3Y Sales & EPS Compounded Growth
Momentum (M)98
Relative Strength & Trend Position
TheScreener Radar™ 5-Pillar Quantitative Scorecard
Holistic quantitative radar evaluating fundamental quality, valuation multiples, balance sheet health, growth, and price momentum
Sector Rank:Rank #30 of 46 in Healthcare
Valuation
Weak32/100
P/E Ratio:55.90x
P/B Ratio:4.25x
Dividend Yield:0.19%
P/E, P/B, EV/EBITDA & Dividend Yield relative to 5Y medians and sector
Growth
Moderate58/100
3Y Sales CAGR:—
3Y PAT CAGR:—
Quarterly YoY:+12.4%
3-Year Compounded Sales & Net Profit Growth trajectory
Profitability
Moderate45/100
ROE:7.6%
ROCE:8.0%
OPM %:—
Return on Equity (ROE), ROCE & Operating Margin efficiency
Solvency & Health
Moderate44/100
Piotroski F-Score:4/9
Altman Z-Score:6.49
Debt / Equity:0.00
Balance Sheet strength, Altman Z-Score & Piotroski F-Score checklist
Momentum
Strong98/100
1Y Return:—
RSI (14):54.2
From 52W High:—
1-Year Relative Strength vs NIFTY 500, RSI-14 & 52W High distance
Quantitative Drivers & Growth Analysis
52-week corridor, deep valuation multiples, compounded CAGR trajectory, and institutional flow shifts
52-Week Low₹33.68
From 52W High+0.00%
52-Week High₹104.11
Valuation MultiplesCash Flow & Yield
PEG Ratio2.72
Earnings Yield122.14%
Price / FCF—
FCF Yield-0.10%
Payout Ratio0.16%
Net-Net Ratio-42.62
Solvency & SafetyPiotroski & Altman
Piotroski F-Score4/9
Altman Z-Score6.49
Graham Number₹264.74
1Y Flow & Margin ShiftsTrailing 12M
FII Stake:▼ 0.13%
DII Stake:—
OPM Margin:▼ 1.64%
Net Margin:▼ 1.26%
Compounded Annual Growth Rate (CAGR Matrix)
Historical Fundamental Trajectory| Metric | QoQ Shift | YoY Shift | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|
| Revenue Growth | ▲ +17.62% | ▲ +34.07% | -0.33% | 8.40% | 8.73% |
| Net Profit Growth | ▲ +258.32% | ▲ +424.65% | -19.61% | 34.86% | -0.46% |
| EPS Growth | ▲ +267.86% | ▲ +415.00% | -38.64% | 20.58% | -8.89% |
Intrinsic Valuation Models & DCF Sensitivity
Institutional DCF & Intrinsic Valuation Studio — MOREPENLAB
2-Stage Discounted Cash Flow, Reverse DCF Implied Growth, and Benjamin Graham & Peter Lynch valuation benchmarks.
DCF Intrinsic Fair Value
₹52.0
Verdict:Overvalued (-50.0%)
Benjamin Graham Number
₹26.3
-74.8% vs CMPPeter Lynch Fair Value
₹6.8
-93.5% vs CMPReverse DCF Implied Growth
25.2% CAGR
Aggressive Expectations (Priced for Perfection)Valuation Spectrum PositioningCMP: ₹104.1
₹0 (Distress)CMP: ₹104DCF: ₹52Graham: ₹26
Scenario Calibration & Sensitivity Levers
Tune Discount Rate (WACC), 5-Year Growth, and Terminal Value to model bear, base, and bull cases.
Discount Rate (WACC)11.5%
Cost of Capital Hurdle
5-Year FCF Growth CAGR6.0%
Assumed stage-1 cash flow expansionTerminal Growth Rate4.5%
Long-term perpetual GDP growth rate5-Year Projected Cash Flow Schedule (₹ Cr)
| Projection Period | Growth Rate | Projected FCF | Discount Factor | Present Value |
|---|---|---|---|---|
| Year 1 | 6% | ₹202 | 0.8969 | ₹181 |
| Year 2 | 6% | ₹214 | 0.8044 | ₹172 |
| Year 3 | 6% | ₹227 | 0.7214 | ₹164 |
| Year 4 | 6% | ₹240 | 0.6470 | ₹156 |
| Year 5 | 6% | ₹255 | 0.5803 | ₹148 |
2D Sensitivity Matrix (WACC vs Terminal Growth Rate)
Click any cell to apply WACC & terminal growth scenario. Values in ₹ / share.| WACC \ g(Terminal) | 3.0% | 4.0% | 4.5% | 5.0% | 6.0% |
|---|---|---|---|---|---|
| 10.0% | ₹55 -47% | ₹62 -40% | ₹67 -35% | ₹73 -30% | ₹89 -15% |
| 11.0% | ₹47 -54% | ₹53 -49% | ₹56 -46% | ₹60 -42% | ₹70 -32% |
| 11.5% | ₹44 -57% | ₹49 -53% | ₹52 -50% | ₹55 -47% | ₹64 -39% |
| 12.0% | ₹42 -60% | ₹46 -56% | ₹48 -54% | ₹51 -51% | ₹58 -44% |
| 13.0% | ₹37 -64% | ₹40 -61% | ₹42 -59% | ₹44 -57% | ₹49 -53% |
Discounted cash flow (DCF) and valuation models are quantitative projections based on user-supplied assumptions — not a forecast, not a guarantee of future performance, and not SEBI-registered investment advice. Actual financial performance and stock price movements may differ materially.
New to intrinsic valuation models? Learn how Discounted Cash Flow and Terminal Growth rates work.Read DCF Academy Guide →
Valuation history
P/E55.90current
ReportedComputed, approximate
P/B4.25current
ReportedComputed, approximate
The dashed line is computed from historical close price divided by the most recently reported annual EPS or book value — not IndianAPI's own figure, which only ever gives a single current reading with no history behind it. Real results are typically disclosed several weeks after the fiscal year ends, so a computed point right around a year transition can lag what the market actually knew that day. The solid line is the real reported figure.
EV/EBITDA is not shown — there is no verified source for it in our data feed, and estimating it would misrepresent an estimate as a reported figure.
| Date | P/E | P/B |
|---|---|---|
| 31 Aug 2026 | 55.90 | 4.25 |
Analyst Consensus, Price Targets & Forecasts
Analyst Ratings
No analyst consensus data available for this company.
Risk Profile & Volatility
Statistical return volatility classification · 31 Aug 2026
High risk
Low RiskModerate RiskHigh Risk
Annualised Standard Deviation:60.30%
Price Target
No analyst target price estimates available for this company.
Forward Financial Forecasts & Consensus Estimates
Institutional broker consensus estimates and forward earnings trajectory
FY2027E11 Analysts
Mean Estimate
₹61.30
Low:—
High:—
FY2027E11 Analysts
Mean Estimate
₹64.52
Low:—
High:—
FY2027E11 Analysts
Mean Estimate
₹67.75
Low:—
High:—
FY2027E11 Analysts
Mean Estimate
₹70.98
Low:—
High:—
FY2028E11 Analysts
Mean Estimate
₹70.36
Low:—
High:—
FY2028E11 Analysts
Mean Estimate
₹74.06
Low:—
High:—
FY2028E11 Analysts
Mean Estimate
₹77.77
Low:—
High:—
FY2028E11 Analysts
Mean Estimate
₹81.47
Low:—
High:—
| Period / Fiscal Year | Consensus Mean | Bull Case (High) | Bear Case (Low) | Brokers |
|---|---|---|---|---|
| FY2027 Forecast | ₹61.30 | — | — | 11 |
| FY2027 Forecast | ₹64.52 | — | — | 11 |
| FY2027 Forecast | ₹67.75 | — | — | 11 |
| FY2027 Forecast | ₹70.98 | — | — | 11 |
| FY2028 Forecast | ₹70.36 | — | — | 11 |
| FY2028 Forecast | ₹74.06 | — | — | 11 |
| FY2028 Forecast | ₹77.77 | — | — | 11 |
| FY2028 Forecast | ₹81.47 | — | — | 11 |
Third-party broker forecasts compiled from institutional research houses, not IndiScreener's proprietary estimates. Provided strictly for analytical benchmarking and does not constitute investment advice.
Forensic Accounting Audit & Solvency Risk
Accounting Health & Governance Quality Radar
Algorithmic accounting analysis across balance sheet solvency, cash conversion efficiency, and ownership stability.
Clean Governance & Solvency
Financial Strengths & Catalysts
2 Factors- •Company maintains conservative leverage with D/E of 0.17x.
- •Net profit has grown at an impressive 34.9% CAGR over 3 years.
Risk Factors & Watchouts
2 Watchouts- •Return on Equity (ROE) is currently modest at 7.6%.
- •Cash conversion lag: Operating Cash Flow is below 50% of reported Net Profit.
Forensic Accounting & Health Audit
Piotroski F-Score, Altman Z-Score Distress Model & Beneish Earnings Manipulation Checks
Piotroski F-Score4 / 9
● Moderate (Neutral)
Altman Z-Score6.49
● Safe Zone
Negligible risk of financial distress over the next 2 years.
Beneish M-Score-2.09
● Low Risk (Clean Accounting)
Cash flows closely match reported earnings with conservative accruals.
Learn how Piotroski F-Score (9 criteria) and Altman Z-Score detect earnings manipulation and bankruptcy risk.Read Forensic Guide →
10-Year Financial Statements & DuPont ROE
Financial Statements
consolidated · amounts in ₹ Crores
Accounting Flow:
Wall Street Cash Flow & Free Cash Flow (FCF) Cascade
FY26 (2025-2026)3-Stage institutional flow from reported earnings to owner Free Cash Flow and capital allocation
FCF Conversion Rate (FCF / PAT)
-137.8%Low Cash Conversion
Measures how much reported accounting profit turns into real liquid cash.
Free Cash Flow Margin
-7.2%of Gross Revenue
Liquid cash retained per ₹100 of top-line revenue generated.
CapEx Reinvestment Rate
538.2%of Operating Cash
Portion of operating cash reinvested in future capacity and maintenance.
Reported Net Profit (PAT)₹95 CrInflow
95
+ D&A Non-Cash Charge₹36 CrAdd-back
36
Working Capital Adjustment-₹101 Cr- Tied Up
101
= Operating Cash Flow (CFO)₹30 CrOperating Cash
30
- Capital Expenditures (CapEx)-₹161 CrReinvestment
161
= Free Cash Flow (FCF)-₹131 CrFree Cash Flow
131
- Dividends & Debt Repayment-₹21 CrCapital Return
21
= Net Change in Cash-₹152 CrNet Balance
152
Multi-Year Historical FCF vs Reported PAT Trajectory:
Free Cash Flow (FCF) Reported Net Profit (PAT)
| Metric | 2018-201931 Mar 2019 | 2019-202031 Mar 2020 | 2020-202131 Mar 2021 | 2021-202231 Mar 2022 | 2022-202331 Mar 2023 | 2023-202431 Mar 2024 | 2024-202531 Mar 2025 | 2025-202631 Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹768.54 | ₹853.07 | ₹1,188.06 | ₹1,546.83 | ₹1,417.53 | ₹1,690.43 | ₹1,811.58 | ₹1,805.69 |
| Operating profit | ₹27.61 | ₹31.61 | ₹88.23 | ₹109.03 | ₹51.60 | ₹125.16 | ₹145.09 | ₹115.02 |
| OPM | 3.59% | 3.71% | 7.43% | 7.05% | 3.64% | 7.40% | 8.01% | 6.37% |
| Net profit | ₹28.85 | ₹33.58 | ₹97.09 | ₹101.68 | ₹38.68 | ₹96.16 | ₹118.02 | ₹94.88 |
| EPS | 0.64 | 0.75 | 2.15 | 1.96 | 0.77 | 1.88 | 2.20 | 1.35 |
| Net margin | 3.75% | 3.94% | 8.17% | 6.57% | 2.73% | 5.69% | 6.51% | 5.25% |
| ROE | 11.40% | 11.82% | 22.86% | 17.57% | 5.14% | 11.35% | 10.21% | 7.61% |
| ROCE | 10.00% | 10.13% | 19.42% | 17.77% | 6.54% | 14.04% | 11.36% | 7.96% |
| Debt / equity | 0.52 | 0.47 | 0.32 | 0.03 | 0.03 | 0.03 | 0.09 | 0.17 |
Compounded growth (CAGR)
| Metric | 1Y | 3Y | 5Y |
|---|---|---|---|
| Revenue | -0.33% | 8.40% | 8.73% |
| Net profit | -19.61% | 34.86% | -0.46% |
| EPS | -38.64% | 20.58% | -8.89% |
Each column only appears when 8 real reported years actually support it — never extrapolated from fewer.
Balance sheet
| Metric | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|
| Total assets | ₹615.18 | ₹663.46 | ₹858.15 | ₹1,070.05 | ₹1,110.50 | ₹1,293.21 | ₹1,778.10 | ₹1,936.12 |
| Total liabilities | ₹362.08 | ₹379.40 | ₹433.40 | ₹491.49 | ₹357.59 | ₹445.98 | ₹621.87 | ₹689.68 |
| Total equity | ₹253.09 | ₹284.06 | ₹424.75 | ₹578.56 | ₹752.91 | ₹847.23 | ₹1,156.23 | ₹1,246.44 |
| Total debt | ₹131.60 | ₹133.12 | ₹136.70 | ₹18.57 | ₹25.16 | ₹29.00 | ₹105.10 | ₹207.86 |
| Cash | ₹9.60 | ₹13.64 | ₹41.39 | ₹14.67 | ₹21.67 | ₹16.95 | ₹27.38 | ₹31.19 |
| Current assets | ₹299.47 | ₹372.18 | ₹526.79 | ₹734.30 | ₹756.16 | ₹889.04 | ₹1,159.37 | ₹1,163.61 |
| Current liabilities | ₹339.17 | ₹351.44 | ₹403.80 | ₹456.46 | ₹321.16 | ₹402.04 | ₹500.65 | ₹490.30 |
| Inventory | ₹111.87 | ₹177.32 | ₹242.75 | ₹392.49 | ₹394.56 | ₹462.73 | ₹557.32 | ₹271.83 |
| Receivables | ₹134.01 | ₹138.24 | ₹182.57 | ₹251.22 | ₹264.23 | ₹326.49 | ₹325.93 | ₹333.14 |
| Payables | ₹168.15 | ₹172.30 | ₹208.85 | ₹258.12 | ₹226.88 | ₹295.03 | ₹363.30 | ₹317.24 |
| Net PP&E | ₹147.37 | ₹134.09 | ₹131.24 | ₹160.79 | ₹184.01 | ₹237.66 | ₹370.33 | ₹415.59 |
| Retained earnings | ₹-2.07 | ₹31.51 | ₹172.34 | ₹256.52 | ₹287.70 | ₹383.86 | ₹501.88 | ₹1,136.85 |
Cash flow
| Metric | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | ₹17.37 | ₹11.02 | ₹50.83 | ₹-57.76 | ₹-91.17 | ₹73.37 | ₹32.06 | ₹29.83 |
| Capital expenditure | ₹-11.84 | ₹-17.07 | ₹-40.40 | ₹-67.37 | ₹-45.97 | ₹-81.34 | ₹-214.24 | ₹-160.54 |
| Free cash flow | ₹5.53 | ₹-6.05 | ₹10.43 | ₹-125.13 | ₹-137.14 | ₹-7.97 | ₹-182.18 | ₹-130.71 |
| OCF / net profit | 0.60 | 0.33 | 0.52 | -0.57 | -2.36 | 0.76 | 0.27 | 0.31 |
| FCF / Capex intensity | 1.54 | 2.00 | 3.40 | 4.36 | 3.24 | 4.81 | 11.83 | 8.89 |
Income statement detail
| Metric | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|
| Gross profit | ₹269.68 | ₹278.56 | ₹388.28 | ₹466.96 | ₹423.38 | ₹572.82 | ₹585.28 | ₹637.38 |
| Cost of revenue | ₹498.86 | ₹574.51 | ₹799.78 | ₹1,079.87 | ₹994.15 | ₹1,117.61 | ₹1,226.30 | ₹1,168.31 |
| EBITDA | ₹67.51 | ₹68.52 | ₹118.51 | ₹136.67 | ₹79.53 | ₹158.63 | ₹174.07 | ₹151.45 |
| Income before tax | ₹29.18 | ₹39.11 | ₹98.51 | ₹126.70 | ₹55.76 | ₹135.42 | ₹155.11 | ₹119.92 |
| Interest expense | ₹1.29 | — | — | — | ₹0.32 | ₹1.21 | ₹1.22 | ₹16.41 |
| Tax expense | ₹0.34 | ₹5.53 | ₹1.42 | ₹25.02 | ₹17.08 | ₹38.80 | ₹37.09 | ₹24.27 |
| D&A | ₹39.90 | ₹36.91 | ₹30.28 | ₹27.64 | ₹27.93 | ₹33.47 | ₹28.98 | ₹36.43 |
| EBITDA margin | 8.78% | 8.03% | 9.98% | 8.84% | 5.61% | 9.38% | 9.61% | 8.39% |
Financial ratios
| Metric | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|
| Current ratio | 0.88 | 1.06 | 1.30 | 1.61 | 2.35 | 2.21 | 2.32 | 2.37 |
| Quick ratio | 0.55 | 0.55 | 0.70 | 0.75 | 1.13 | 1.06 | 1.20 | 1.82 |
| Interest coverage | 21.40 | — | — | — | 161.25 | 103.44 | 118.93 | 7.01 |
| Inventory days | 81.85 | 112.66 | 110.79 | 132.66 | 144.86 | 151.12 | 165.88 | 84.92 |
| Receivable days | 63.64 | 59.15 | 56.09 | 59.28 | 68.04 | 70.50 | 65.67 | 67.34 |
| Payable days | 123.03 | 109.47 | 95.31 | 87.25 | 83.30 | 96.35 | 108.13 | 99.11 |
| Cash conversion cycle | 22.47 | 62.34 | 71.56 | 104.70 | 129.60 | 125.27 | 123.42 | 53.15 |
| Working capital days | — | — | — | — | — | — | — | — |
| Fixed asset turnover | 5.22 | 6.36 | 9.05 | 9.62 | 7.70 | 7.11 | 4.89 | 4.34 |
| ROA | 4.69% | 5.06% | 11.31% | 9.50% | 3.48% | 7.44% | 6.64% | 4.90% |
| ROIC | 7.28% | 6.73% | 16.72% | 15.02% | 4.73% | 10.39% | 8.95% | 6.45% |
| Gross margin | 35.09% | 32.65% | 32.68% | 30.19% | 29.87% | 33.89% | 32.31% | 35.30% |
DuPont 3-Stage ROE Factor Decomposition
Deconstructing Return on Equity into Profitability, Asset Efficiency, and Financial Leverage
Balanced Return EngineFY2025-2026
Net marginProfitability
5.25%
Net Profit generated per ₹100 of revenue (Profitability)
×
Asset turnoverEfficiency
0.93
Revenue generated per ₹1 of total assets (Capital Efficiency)
×
Equity multiplierLeverage
1.55
Total assets supported per ₹1 of shareholder equity (Leverage)
=
Implied DuPont ROEFinal Output
7.61%
Reported: 7.61%
Explore the 3-Stage DuPont Formula: Net Margin × Asset Turnover × Leverage Multiplier.Read DuPont Guide →
Corporate Actions, Dividends & Capital Changes
Chronological Corporate Actions Registry
Historical stock splits, bonus shares, rights issues, and corporate schemes
| Year | Execution Date | Action Type | Ratio / Term |
|---|---|---|---|
| 2026 | 19 Sept 2026 | dividend | 10% |
| 2025 | 30 Aug 2025 | dividend | 10% |
Dividend Intelligence & Capital Return History
Historical cash payout track record across 2 dividend distributions
Latest Year DPS:₹0.20
Yield on CMP:0.19%
Annual Dividend Payout Progression (Per Share)Total Cumulative DPS: ₹0.40
₹0.2
2026
₹0.2
2025
| Ex-Date | Amount (Per Share) | Dividend Type |
|---|---|---|
| 18 Sept 2026 | ₹0.20 | Final |
| 29 Aug 2025 | ₹0.20 | Final |
Industry Peer Group & Valuation Spread
Compare valuation multiples and market cap relative to sector competitors
Diagnostic Devices & APIs
No Industry Peers Found
No other company in our universe is listed under Diagnostic Devices & APIs.
Regulatory Filings & Market Intelligence
Corporate Filings & Document Vault
SEBI LODR VerifiedAudited Annual Reports, Investor Decks, Earnings Concall Transcripts, and Board Resolutions for Morepen Laboratories Ltd (MOREPENLAB)
Indexed Documents8 Filings
Latest Disclosure31 Jul 2026
Corporate Action31 Jul 2026
Morepen Laboratories Ltd: Recommendation of Final Dividend for the Financial Year 2025-26
Concall Transcript28 Jul 2026
Morepen Laboratories Ltd: Transcript of Earnings Conference Call with Institutional Investors
Investor Deck25 May 2026
Morepen Laboratories Ltd: Investor Presentation on Q4 Financial Results and Growth Outlook
Shareholding20 May 2026
Morepen Laboratories Ltd: Quarterly Statement of Shareholding Pattern filed with NSE/BSE
Secretarial Filing17 Apr 2026
Morepen Laboratories Ltd: Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015
Board Outcome29 Mar 2026
Morepen Laboratories Ltd: Outcome of Board Meeting for Approval of Audited Financial Results
AGM / EGM23 Mar 2026
Morepen Laboratories Ltd: Notice of Annual General Meeting and Record Date for Dividend
News
- IndianAPIBuy or sell: Gift Nifty signals gap-up start | Vaishali Parekh recommends three stocks to buy today — 27 August 2026
Buy or sell: Vaishali Parekh recommends three stocks to buy today — Vedanta Oil and Gas, Morepen Laboratories, and Marksans Pharma
- IndianAPIStocks under ₹100: Sumeet Bagadia recommends three shares to buy on Monday - 17 August 2026
The Indian stock ended the week on a negative note on Friday. Check Sumeet Bagadia's outlook for the market in the coming with, along with the three stocks under ₹100 that he feels are a buy in current situation.
- IndianAPIBreakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 30 July 2026
Breakout stocks to buy or sell: Sumeet Bagadia recommends five breakout stocks to buy today — Gland Pharma, PG Electroplast, Morepen Laboratories, Allied Blenders & Distillers, and Hexaware Technologies.
- IndianAPIStocks to buy under ₹100: Sumeet Bagadia recommends three stocks to buy on Monday - 29 June 2026
The Indian stock ended the week on a positive note on Friday. Check Sumeet Bagadia's outlook for the market in the coming with, along with the three stocks under ₹100 that he feels are a buy in current situation.
- IndianAPIBuy or sell: Gift Nifty trades flat, Vaishali Parekh recommends three stocks to buy today — 27 May 2026
Buy or sell: Vaishali Parekh recommends three stocks to buy today — Morepen Laboratories, Radico Khaitan, and AU Small Finance Bank
- IndianAPIBuy or sell: Gift Nifty down, Vaishali Parekh recommends three stocks to buy today —11 May 2026
Buy or sell: Gift Nifty down, Vaishali Parekh recommends three stocks to buy today — Morepen Laboratories, Reliance, and AU Small Finance Bank
- IndianAPIStocks to buy under ₹100: Sumeet Bagadia recommends three stocks to buy on Monday - 11 May 2026
The Indian stock ended the week on a weak note on Friday. Check Sumeet Bagadia's outlook for the market in the coming with, along with the three stocks under ₹100 that he feels are a buy in current situation.
- IndianAPIFrom IDFC First Bank to Ola Electric Mobility— These are the top most traded stocks on the NSE today
IDFC First Bank shares fell 20% after a ₹590 crore fraud report, while Vodafone Idea dropped 2.6%. Morepen Laboratories surged 19% after securing an ₹825 crore contract. Ola Electric hit a 52-week low, and Easy Trip Planners saw a 3% decline amid profit booking.
For informational and educational purposes only. Not investment advice. Data may be delayed or incomplete. Consult a SEBI-registered investment adviser before making investment decisions.